Atenolol

Atenolol is a beta-blocker taken by mouth. The US label read, for Tenormin, lists three uses: hypertension, to lower blood pressure; the long-term management of patients with angina pectoris; and, in hemodynamically stable patients with definite or suspected acute myocardial infarction, reducing cardiovascular mortality.

Also called Tenormin

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 1202; UNII 50VV3VW0TI. MeSH descriptor D001262 is Atenolol. Class: beta-Adrenergic Blocker (FDA established pharmacologic class, RxClass). The label read is the Upsher-Smith Laboratories, LLC label for TENORMIN (atenolol), application NDA018240, effective 2025-09-18 in openFDA. Other atenolol labels in openFDA, from generic sponsors and repackagers, were not read. This page records label indications and the class only: no trial result and no dose is given.

Trials at a glance

The figures count the 5 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
5
Phase 3 or 4
4
Recruiting
0
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseCompletedTerminatedUnknown statusAll statuses
Phase 20011
Phase 30101
Phase 41113
All phases1225

Conditions these trials study

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

About this drug

Level
Substance
Mechanism
Not reported

Claims and evidence

Context People for whom the US label of atenolol (Tenormin) lists an indication: hypertension, angina pectoris, definite or suspected acute myocardial infarction

Recipient
Recipient not specified
Population
Patients described in the indications section of the label. The label does not state an age range in the passages read.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the label passages read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 3 inclusion criteria; exclusion criteria not stated
Included
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of TENORMIN (atenolol), in the Upsher-Smith Laboratories, LLC version dated 2025-09-18 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure; for the long-term management of patients with angina pectoris; and for hemodynamically stable patients with definite or suspected acute myocardial infarction, to reduce cardiovascular mortality.

    Applies to Recipient not specified People for whom the US label of atenolol (Tenormin) lists an indication: hypertension, angina pectoris, definite or suspected acute myocardial infarction

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-08
    Next evidence check due
    Not scheduled
    Sources and citations (2)
    1. Supports openFDA drug label record for TENORMIN (atenolol), Upsher-Smith Laboratories, LLC label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 6e850b1e-28a4-4ff8-8ed7-bb0b29faa28a (manufacturer Upsher-Smith Laboratories, LLC, application NDA018240), returned on 2026-11-08. The label text is dated 2025-09-18 (effective_time). Other openFDA records of atenolol labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], INDICATIONS AND USAGE
      How it applies
      The label sentences that give the indications named in the statement, each quoted in the research quote table.
      Retrieved
      Source effective date
      2025-09-18
      Source state
      Current
      Version fingerprint
      16fc3b394ebc3edfdc3713d69728e637bce0d7771e3e123eb168492146835def
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-08, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for TENORMIN (atenolol), Upsher-Smith Laboratories, LLC label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 6e850b1e-28a4-4ff8-8ed7-bb0b29faa28a (manufacturer Upsher-Smith Laboratories, LLC, application NDA018240), returned on 2026-11-08. The label text is dated 2025-09-18 (effective_time). Other openFDA records of atenolol labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20250918.
      Retrieved
      Source effective date
      2025-09-18
      Source state
      Current
      Version fingerprint
      16fc3b394ebc3edfdc3713d69728e637bce0d7771e3e123eb168492146835def
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-08, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

FDA label

The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.

TENORETIC 100

No label from the application holder was found in the openFDA label dataset for application NDA018760. This page does not show another labeler's label in its place.

TENORMIN

No label from the application holder was found in the openFDA label dataset for application NDA018240. This page does not show another labeler's label in its place.

TENORMIN

No label from the application holder was found in the openFDA label dataset for application NDA019058. This page does not show another labeler's label in its place.

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.

  1. Approval NDA018240 TENORMIN
  2. Approval NDA018760 TENORETIC 100
  3. Supplemental approval NDA018240 TENORMIN
  4. Supplemental approval NDA018240 TENORMIN
  5. Approval NDA019058 TENORMIN
  6. Supplemental approval NDA018240 TENORMIN

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Registry records

Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry products 3

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 3 efficacy supplement approvals on record.

    ProductNDA018240

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record. FDA lists it under 2 brand...

    ProductNDA018760

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA019058

Record details

Record id
cardio:atenolol
Content hash
cc4c887dd5c1e57df4e6422f937acbb52a3bf8d2b1ef70454003e4cfd158085e